1 The Safety and Efficacy Of Cangrelor, a Short Acting, IV, Reversible, Platelet P2Y 12 Inhibitor In Patients Awaiting Cardiac Surgery: Results Of the.
Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries-BIOSOLVE-II.
Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial Aldo.
Fundamental Wire Technick in CTO
GP Superclinic@Midland Railway Workshops Heart Week Event Dr Chris Judkins MBBS MClinRes FRACP Interventional Cardiologist WA Cardiology Fiona Stanley.
A Pharmacodynamic Evaluation of Switching from Ticagrelor to Prasugrel in Subjects with Stable Coronary Artery Disease: Results of the SWAP-2 Study A Pharmacodynamic.
COI Disclosure for Dr. Montalescot: Research Grants to the Institution or Consulting/Lecture Fees from Abbott Vascular, Astra-Zeneca, Bayer, Biotronik,
Bioabsorbable Stents The Ideal Scaffold properties and kinetics Jonathan Hill King’s College Hospital King’s Health Partners BIOABSORBABLE STENTS Chairs:
Quoi de neuf du côté des cathéters guide?
Gregg W. Stone, MD Manejeh Yaqub, MD; Poornima Sood, MD, MBA; Ali Rizvi, MD;
Two Year Safety And Clinical Performance Of The Drug Eluting Orsiro Stent In The Treatment Of Subjects With Single De Novo Coronary Artery Lesions (BIOFLOW-II)
Dual Antiplatelet Therapy (DAPT) Duration Dilemma: Recent Trials And Guidelines For Clinical Practice Dean J. Kereiakes, MD FACC FSCAI Medical Director,
